{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:06:24Z","timestamp":1770069984099,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.leukres.2023.107324","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T20:54:12Z","timestamp":1684875252000},"page":"107324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-4883","authenticated-orcid":false,"given":"Agrima","family":"Mian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-9539","authenticated-orcid":false,"given":"Ahsan","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Aljama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Koehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irbaz","family":"Bin Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15_suppl","key":"10.1016\/j.leukres.2023.107324_bib1","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","article-title":"Continued improvement in survival in multiple myeloma (MM) including high-risk patients","volume":"37","author":"Nandakumar","year":"2019","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.leukres.2023.107324_bib2","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2023.107324_bib3","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cancers13071571","article-title":"Monoclonal antibodies and antibody drug conjugates in multiple myeloma","volume":"13","author":"Radocha","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.leukres.2023.107324_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council\u2019s working party on leukaemia in adults","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2023.107324_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bjh.15426","article-title":"Second primary malignancy after multiple myeloma-population trends and cause-specific mortality","volume":"182","author":"Costa","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107324_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","article-title":"Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study","volume":"65","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107324_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100757","article-title":"Secondary primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev."},{"issue":"29","key":"10.1016\/j.leukres.2023.107324_bib8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2023.107324_bib9","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107324_bib10","unstructured":"761113s003lbl.pdf [Internet]. [cited 2022 May 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761113s003lbl.pdf."},{"issue":"10214","key":"10.1016\/j.leukres.2023.107324_bib11","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.leukres.2023.107324_bib12","doi-asserted-by":"crossref","first-page":"21916","DOI":"10.1038\/s41598-021-01440-x","article-title":"Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Kiss","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2023.107324_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107324_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.leukres.2023.107324_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107324_bib16","unstructured":"Higgins J.P., Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series.:674."},{"issue":"24","key":"10.1016\/j.leukres.2023.107324_bib17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107324_bib18","unstructured":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | The BMJ [Internet]. [cited 2022 May 28]. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71."},{"key":"10.1016\/j.leukres.2023.107324_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.leukres.2023.107324_bib20","first-page":"367","article-title":"Meta-analysis of rare and adverse event data","volume":"2","author":"Sutton","year":"2002","journal-title":"Expert Rev. Pharm. Outcomes Res"},{"issue":"1","key":"10.1016\/j.leukres.2023.107324_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat. Med"},{"issue":"9","key":"10.1016\/j.leukres.2023.107324_bib22","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study","volume":"21","author":"Lu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10218","key":"10.1016\/j.leukres.2023.107324_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.leukres.2023.107324_bib24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107324_bib25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2023.107324_bib26","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107324_bib27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2023.107324_bib28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2023.107324_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10292","key":"10.1016\/j.leukres.2023.107324_bib30","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.leukres.2023.107324_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107324_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107324_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107324_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: a review of its use in multiple myeloma","volume":"16","author":"Frampton","year":"2021","journal-title":"Target Oncol."},{"key":"10.1016\/j.leukres.2023.107324_bib35","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol."},{"issue":"15","key":"10.1016\/j.leukres.2023.107324_bib36","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2023.107324_bib37","unstructured":"sarclisa-epar-product-information_en.pdf [Internet]. [cited 2022 Apr 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf."},{"issue":"2","key":"10.1016\/j.leukres.2023.107324_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"0","key":"10.1016\/j.leukres.2023.107324_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1188\/11.S1.CJON.25-40","article-title":"Board the IMFNL. Routine health maintenance in patients living with multiple myeloma","volume":"15","author":"Bilotti","year":"2011","journal-title":"Clin. J. Oncol. Nurs."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623005891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623005891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:43Z","timestamp":1758935023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623005891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":39,"alternative-id":["S0145212623005891"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107324","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107324"}}